Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine - PubMed (original) (raw)
Jian-San Zhang, Nan Su, Jian-Guo Xu, Nan Wang, Jiang-Ting Chen, Xin Chen, Yu-Xuan Liu, Hong Gao, Yu-Ping Jia, Yan Liu, Rui-Hua Sun, Xu Wang, Dong-Zheng Yu, Rong Hai, Qiang Gao, Ye Ning, Hong-Xia Wang, Ma-Chao Li, Biao Kan, Guan-Mu Dong, Qi An, Ying-Qun Wang, Jun Han, Chuan Qin, Wei-Dong Yin, Xiao-Ping Dongs
Affiliations
- PMID: 18018769
Clinical Trial
Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine
Jiang-Tao Lin et al. Antivir Ther. 2007.
Abstract
Background: Emergence of severe acute respiratory syndrome (SARS) from the winter of 2002 to the spring of 2003 has caused a serious threat to public health.
Methods: To evaluate the safety and immunogenicity of the inactivated SARS coronavirus (SARS-CoV) vaccine, 36 subjects received two doses of 16 SARS-CoV units (SU) or 32 SU inactivated SARS-CoV vaccine, or placebo control.
Results: On day 42, the seroconversion reached 100% for both vaccine groups. On day 56, 100% of participants in the group receiving 16 SU and 91.1% in the group receiving 32 SU had seroconverted. The geometric mean titre of neutralizing antibody peaked 2 weeks after the second vaccination, but decreased 4 weeks later.
Conclusion: The inactivated vaccine was safe and well tolerated and can elicit SARS-CoV-specific neutralizing antibodies.
Similar articles
- Immunogenicity of SARS inactivated vaccine in BALB/c mice.
Xiong S, Wang YF, Zhang MY, Liu XJ, Zhang CH, Liu SS, Qian CW, Li JX, Lu JH, Wan ZY, Zheng HY, Yan XG, Meng MJ, Fan JL. Xiong S, et al. Immunol Lett. 2004 Sep;95(2):139-43. doi: 10.1016/j.imlet.2004.06.014. Immunol Lett. 2004. PMID: 15388253 Free PMC article. - A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses.
Spruth M, Kistner O, Savidis-Dacho H, Hitter E, Crowe B, Gerencer M, Brühl P, Grillberger L, Reiter M, Tauer C, Mundt W, Barrett PN. Spruth M, et al. Vaccine. 2006 Jan 30;24(5):652-61. doi: 10.1016/j.vaccine.2005.08.055. Epub 2005 Aug 26. Vaccine. 2006. PMID: 16214268 Free PMC article. - Humoral immune responses in rabbits induced by an experimental inactivated severe acute respiratory syndrome coronavirus vaccine prepared from F69 strain.
Zhang CH, Guo ZM, Zheng HY, Lu JH, Wang YF, Yan XG, Zhao Y, DU XW, Zhang X, Fang L, Ling WH, Qi SY, Yu XB, Zhong NS. Zhang CH, et al. Chin Med J (Engl). 2004 Nov;117(11):1625-9. Chin Med J (Engl). 2004. PMID: 15569476 - Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus.
Cavanagh D. Cavanagh D. Avian Pathol. 2003 Dec;32(6):567-82. doi: 10.1080/03079450310001621198. Avian Pathol. 2003. PMID: 14676007 Free PMC article. Review. - SARS Immunity and Vaccination.
Zhu M. Zhu M. Cell Mol Immunol. 2004 Jun;1(3):193-8. Cell Mol Immunol. 2004. PMID: 16219167 Review.
Cited by
- Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?
Al-Kassmy J, Pedersen J, Kobinger G. Al-Kassmy J, et al. Viruses. 2020 Aug 7;12(8):861. doi: 10.3390/v12080861. Viruses. 2020. PMID: 32784685 Free PMC article. Review. - From SARS to MERS, Thrusting Coronaviruses into the Spotlight.
Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, Zhu H, Zhao W, Han Y, Qin C. Song Z, et al. Viruses. 2019 Jan 14;11(1):59. doi: 10.3390/v11010059. Viruses. 2019. PMID: 30646565 Free PMC article. Review. - A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge.
Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M, Funkhouser W, Gralinski L, Totura A, Heise M, Baric RS. Bolles M, et al. J Virol. 2011 Dec;85(23):12201-15. doi: 10.1128/JVI.06048-11. Epub 2011 Sep 21. J Virol. 2011. PMID: 21937658 Free PMC article. - Vaccines for the common cold.
Simancas-Racines D, Franco JV, Guerra CV, Felix ML, Hidalgo R, Martinez-Zapata MJ. Simancas-Racines D, et al. Cochrane Database Syst Rev. 2017 May 18;5(5):CD002190. doi: 10.1002/14651858.CD002190.pub5. Cochrane Database Syst Rev. 2017. PMID: 28516442 Free PMC article. Updated. Review. - The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies.
Molaei S, Dadkhah M, Asghariazar V, Karami C, Safarzadeh E. Molaei S, et al. Int Immunopharmacol. 2021 Mar;92:107051. doi: 10.1016/j.intimp.2020.107051. Epub 2020 Sep 29. Int Immunopharmacol. 2021. PMID: 33429331 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous